For nerve pain, the practical top pick is a CBD-dominant full-spectrum product that carries only trace THC (under 0.3 percent, the federal hemp cutoff). It gives you something you can use during a workday without the impairment THC brings. The second option, THC-dominant flower, vape, or a balanced 1:1 edible, earns its place for overnight flares and for nerve pain that shrugs off everything else. This comparison weighs five things: onset and duration, psychoactive effect and daily function, legal status, how precisely you can control the dose, and how strong the published evidence really is.

related article

Top pick: CBD-dominant full-spectrum (high CBD, trace THC)

Full-spectrum matters here. A wide CBD product with a small amount of THC and the other plant compounds is the closest thing to an all-day nerve pain tool in the legal hemp market, and it does not put you on the couch.

more on this topic

Best for: daytime burning, tingling, and numbness in feet and hands, and for anyone who cannot afford to be impaired.

related article

Runner-up: THC-dominant or balanced 1:1

THC does the heavy lifting for severe nerve pain in most user reports, and a 1:1 ratio blends THC's punch with CBD's calmer profile.

medical cannabis neuropathy dosage

Best for: nighttime, severe flares, and patients in legal states who have a place to be impaired.

Where the two diverge most

Onset separates them more than strength. Inhaled THC hits in five to fifteen minutes, while a CBD tincture can take an hour. Duration runs the other way in practice: many users get three to six hours from CBD and two to four from inhaled THC. Impairment is the second fault line. CBD at reasonable doses does not intoxicate most people, THC does.

Who should pick which

  1. New to cannabinoids and want to keep working: CBD-dominant tincture, low and slow.
  2. Nerve pain that wakes you at night: THC or 1:1 edible taken 90 minutes before bed.
  3. Diabetic peripheral neuropathy with daytime tingling: CBD-dominant, paired with your existing regimen.
  4. Chemotherapy-induced neuropathy in a legal state: discuss a balanced 1:1 with your clinician first.

Safety, legality, and the evidence

Neither cannabinoid is a cure, and neither is FDA-approved for neuropathy. The FDA has approved only one CBD drug, and it treats specific seizure disorders, not nerve pain. Clinical trials of inhaled cannabis for neuropathic pain show modest short-term pain reduction, not dramatic reversal, and side effects like dizziness and sedation appear often. Standard care still centers on treating the cause, diabetes control above all, plus drugs such as gabapentin, duloxetine, and tricyclics. Treat cannabinoids as an add-on, tell your prescriber what you use, and start at the lowest dose that does anything at all.